Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
Due to questions raised by the applicants on the call conditions and clarifications provided shortly before the call deadline. The deadline of HORIZON-MISS-2022-SOCIALCAT-01 is extended until 6th October 2022, 17:00 Brussels Time.
Source: Funding and Tenders Portal
2023-12-08
|
2 days ago |
New European Partnership for Personalised Medicine established & pre-announcement fir... |
2023-10-18
|
1 month ago |
Submitted proposals - HORIZON-MISS-2023-CIT-02 (call closed on 6 September 2023) |
2023-10-17
|
1 month ago |
Submitted proposals - HORIZON-MISS-2023-OCEAN-SOIL-01 (call closed on 20 September 20... |
2023-10-09
|
2 months ago |
Last few days to respond to survey: help us further improve NCP Flanders services |
2023-09-27
|
2 months ago |
NCP Flanders survey still open until 13 October |
2023-09-26
|
2 months ago |
HORIZON-MISS-2023-SOIL-01 – Number of submitted proposals |
2023-09-26
|
2 months ago |
HORIZON-MISS-2023-CLIMA-OCEAN-SOIL-01 – Number of submitted proposals |
2023-09-26
|
2 months ago |
HORIZON-MISS-2023-OCEAN-01 – Number of submitted proposals |
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.